Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 1/2010

01.02.2010 | Original Article

Disease severity in sibling pairs with type 1 Gaucher disease

verfasst von: Deborah Elstein, Ayelet Gellman, Gheona Altarescu, Aya Abrahamov, Irith Hadas-Halpern, Mici Phillips, Maya Margalit, Ehud Lebel, Menachem Itzchaki, Ari Zimran

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

The only prognostic markers in Gaucher disease, the most common lysosomal storage disorder, are young age at first symptom/sign and the presence of null/severe mutations, both being predictive of more severe phenotypes. Therefore, it would be helpful to know whether siblings with the same genotype can be expected to experience comparable phenotypic expression. All non-neuronopathic sibling pairs in our referral clinic (1993–2008) with the same genotype were included. For each pair, gender, date of birth, severity score index at presentation, age at diagnosis and first symptom/sign, presence of bone involvement, spleen status, and use of enzyme replacement therapy were tabulated. There were 90 pairs of siblings: two sets of identical twins; 24 pairs of brothers, 24 pairs of sisters, and 42 pairs of mixed gender. For all measures of disease severity used, only in sibling pairs with an older sister and a younger brother were phenotypes significantly different between siblings. Thus, this large cohort of sibling pairs with type 1 Gaucher disease confirmed that, in general, the phenotypic expression in the younger sibling will be similar enough to that of an older affected sibling that genetic counseling may use those findings in a prognostic way.
Literatur
Zurück zum Zitat Amato D, Stachiw T, Clarke JT, Rivard GE (2004) Gaucher disease: variability in phenotype among siblings. J Inherit Metab Dis 27:659–669CrossRefPubMed Amato D, Stachiw T, Clarke JT, Rivard GE (2004) Gaucher disease: variability in phenotype among siblings. J Inherit Metab Dis 27:659–669CrossRefPubMed
Zurück zum Zitat Barton NW, Brady RO, Dambrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324:1464–1470PubMedCrossRef Barton NW, Brady RO, Dambrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324:1464–1470PubMedCrossRef
Zurück zum Zitat Beutler E, Grabowski GA (2001) Gaucher disease. In: Scriver CR, Valle D, Beudet A et al (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3635–3668 Beutler E, Grabowski GA (2001) Gaucher disease. In: Scriver CR, Valle D, Beudet A et al (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3635–3668
Zurück zum Zitat Elstein D, Abrahamov A, Hadas-Halpern I, Meyer A, Zimran A (1998) Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. Q J Med 91:483–488 Elstein D, Abrahamov A, Hadas-Halpern I, Meyer A, Zimran A (1998) Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. Q J Med 91:483–488
Zurück zum Zitat Lachmann RH, Grant IR, Halsall D, Cox TM (2004) Twin pairs showing discordance of phenotype in adult Gaucher’s disease. Q J Med 97:199–204 Lachmann RH, Grant IR, Halsall D, Cox TM (2004) Twin pairs showing discordance of phenotype in adult Gaucher’s disease. Q J Med 97:199–204
Zurück zum Zitat Levy-Lahad E, Zimran A (1997) Gaucher’s disease: genetic counselling and population screening. Baillieres Clin Haematol 10:779–792CrossRefPubMed Levy-Lahad E, Zimran A (1997) Gaucher’s disease: genetic counselling and population screening. Baillieres Clin Haematol 10:779–792CrossRefPubMed
Zurück zum Zitat Ramsay SL, Maire I, Bindloss C et al (2004) Determination of oligosaccharides and glycolipids in amniotic fluid by electrospray ionisation tandem mass spectrometry: in utero indicators of lysosomal storage diseases. Mol Genet Metab 83:231–238CrossRefPubMed Ramsay SL, Maire I, Bindloss C et al (2004) Determination of oligosaccharides and glycolipids in amniotic fluid by electrospray ionisation tandem mass spectrometry: in utero indicators of lysosomal storage diseases. Mol Genet Metab 83:231–238CrossRefPubMed
Zurück zum Zitat Whitfield PD, Nelson P, Sharp PC et al (2002) Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity. Mol Genet Metab 75:46–55CrossRefPubMed Whitfield PD, Nelson P, Sharp PC et al (2002) Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity. Mol Genet Metab 75:46–55CrossRefPubMed
Zurück zum Zitat Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E (1989) Prediction of severity of Gaucher’s disease by identification of mutations at DNA level. Lancet 2:349–352CrossRefPubMed Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E (1989) Prediction of severity of Gaucher’s disease by identification of mutations at DNA level. Lancet 2:349–352CrossRefPubMed
Zurück zum Zitat Zimran A, Elstein D, Kannai R et al (1994) Low-dose enzyme replacement therapy for Gaucher’s disease: effects of age, sex, genotype, and clinical features on response to treatment. Am J Med 97:3–13CrossRefPubMed Zimran A, Elstein D, Kannai R et al (1994) Low-dose enzyme replacement therapy for Gaucher’s disease: effects of age, sex, genotype, and clinical features on response to treatment. Am J Med 97:3–13CrossRefPubMed
Zurück zum Zitat Zimran A, Abrahamov A, Elstein D (2000) Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy. Isr Med Assoc J 2:182–183PubMed Zimran A, Abrahamov A, Elstein D (2000) Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy. Isr Med Assoc J 2:182–183PubMed
Zurück zum Zitat Zimran A, Morris E, Mengel E et al (2009) The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis 43:264–288CrossRefPubMed Zimran A, Morris E, Mengel E et al (2009) The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis 43:264–288CrossRefPubMed
Metadaten
Titel
Disease severity in sibling pairs with type 1 Gaucher disease
verfasst von
Deborah Elstein
Ayelet Gellman
Gheona Altarescu
Aya Abrahamov
Irith Hadas-Halpern
Mici Phillips
Maya Margalit
Ehud Lebel
Menachem Itzchaki
Ari Zimran
Publikationsdatum
01.02.2010
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 1/2010
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-009-9024-7

Weitere Artikel der Ausgabe 1/2010

Journal of Inherited Metabolic Disease 1/2010 Zur Ausgabe

Images in Metabolic Medicine

Tumoral calcinosis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.